Also trades as: 0J2O.L (LSE) · $vol 0M
HALO NASDAQ
Halozyme Therapeutics, Inc.
1W: +4.5%
1M: +12.4%
3M: +53.4%
YTD: +82.1%
1Y: +91.4%
3Y: +257.6%
5Y: +244.9%
$128.50
+0.49 (+0.38%)
After Hours: $128.53 (+0.03, +0.02%)
Weekly Expected Move ±4.8%
$114
$120
$126
$132
$138
Credit Risk of going bust: lower than 70% of companies Debt: 12.9% of company value Bonds: $229.7M held by 80 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.53B.
Distance to default 7.61 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.53B.
Distance to default 7.61 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.20
Neutral
5 bullish
1 neutral
3 bearish
Articles (7d)
9
Daily Sentiment (7 Days)
Articles (100)
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
11,095 Halozyme Therapeutics, Inc. $HALO Shares Purchased by Gibbs Wealth Management
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
The Zacks Analyst Blog Highlights Chord Energy, Halozyme, Sezzle, SanDisk and Teradyne
5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings
ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
Quality stocks breaking out as mid-cycle shift accelerates - Morgan Stanley
Zacks.com featured highlights include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics
Halozyme Therapeutics, Inc. $HALO Stock Position Cut by First Citizens Bank & Trust Co.
5 Stocks to Buy Using the Relative Price Strength Strategy
Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
Top Research Reports for Mastercard, AstraZeneca & Sandisk
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
Argenx falls after ending late-stage trial for Sjögren's disease therapy
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
Merck’s injectable Keytruda barred in Europe as Halozyme wins injunction
What's next for personalized mRNA cancer vaccines?
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
Why Women-Run Companies Deserve a Place in Your Portfolio
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Sequoia Financial Advisors LLC Makes New $359,000 Investment in Halozyme Therapeutics, Inc. $HALO
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Halozyme prices $1.3B convertible senior notes offering due 2033
10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades
Bank of America Corp DE Makes New $214.50 Million Investment in Halozyme Therapeutics, Inc. $HALO
Halozyme Therapeutics plans a $1.05B convertible notes sale
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Zacks.com featured highlights include Halozyme Therapeutics, Avnet, BILL and Venture Global
4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike Fears
4 Best PEG Value Stocks to Buy Now for Strong Growth & Return
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $1.02 Million Position in Halozyme Therapeutics, Inc. $HALO
Squarepoint Ops LLC Sells 25,257 Shares of Halozyme Therapeutics, Inc. $HALO
California State Teachers Retirement System Purchases 10,531,698 Shares of Halozyme Therapeutics, Inc. $HALO
Hsbc Holdings PLC Purchases 130,108 Shares of Halozyme Therapeutics, Inc. $HALO
4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
Ten healthcare stocks leading in year-over-year CapEx growth
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
Highest and lowest quant-rated healthcare stocks above $10B cap after earnings season
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
Canada Pension Plan Investment Board Purchases Shares of 132,600 Halozyme Therapeutics, Inc. $HALO
Freestone Grove Partners LP Acquires New Stake in Halozyme Therapeutics, Inc. $HALO
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Zacks.com featured highlights Herbalife, Honda Motor, Marathon, Halozyme and Genworth
5 Value Stocks to Buy Right Now as Inflation Remains Sticky
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
5 Biotech Stocks Worth Adding to Your Portfolio Now
Argenx upgraded at UBS; sees $20B peak sales in Vyvgart
Biotech Breakout: What's in focus after Moderna's cancer win?
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?
Allworth Financial LP Acquires New Shares in Halozyme Therapeutics, Inc. $HALO
HALO Stock Rises 36% in a Month: Here's What You Should Know
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Halozyme (HALO) Q2 2026 Earnings Call Transcript
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?
Halozyme Therapeutics (HALO) Is Up 24.9% After Record Q2, Higher 2026 Guidance And New ENHANZE Deals - Has The Bull Case Changed? - simplywall.st
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks - Yahoo Finance UK
ETFs Investing in Halo Microelectronics Co., Ltd. Class A Stocks - TradingView
Halozyme Therapeutics (HALO) Stock Looks Expensive At Today’s Price - Sahm
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise? - Yahoo Finance
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?
Halozyme (HALO) Stock Rallies As Royalties Surge And Guidance Climbs - simplywall.st
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
Assenagon Asset Management S.A. Has $78.09 Million Position in Halozyme Therapeutics, Inc. $HALO
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know - StockStory
Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...
Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up - Yahoo Finance
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
3 HALO Stocks to Buy Now - The Globe and Mail
Halozyme climbs after record Q2 results and higher 2026 outlook - Quiver Quantitative
3 HALO Stocks to Buy Now - Yahoo Finance
Halozyme Therapeutics, Inc. Q2 2026 Earnings Call Summary
Halozyme Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HALO) 2026-08-07 - Seeking Alpha
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance - StockStory
Halozyme Therapeutics Q2 Earnings Call Highlights
Halozyme projects 2026 non-GAAP EPS of $8.65-$9.00 while raising revenue outlook to $1.835B-$1.91B
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance